Selenium compounds regulate p53 by common and distinctive mechanisms

Anticancer Research

Volumn 24, Issue 3 A, 2004, Pages 1401-1408

  Smith, Martin L ^a   Lancia, Jody K ^a   Mercer, Timothy I ^a   Ip, C ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cancer chemoprevention; DNA repair; Field effect; Selenium compounds

Indexed keywords

CYSTEINE; METHYLSELENINIC ACID; PROTEIN P53; SELENIUM DERIVATIVE; SELENOMETHIONINE; SERINE; SODIUM SELENITE; THIOL DERIVATIVE; THREONINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER PREVENTION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIET; DNA DAMAGE; DNA REPAIR; EMBRYO; GENE ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REPORTER GENE; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CYSTEINE; DNA REPAIR; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; HUMANS; LUNG NEOPLASMS; ORGANOSELENIUM COMPOUNDS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SELENOMETHIONINE; SERINE; SIGNAL TRANSDUCTION; SODIUM SELENITE; THREONINE; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 3242736745     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Ip C: Prophylaxis of mammary neoplasia by selenium supplementation in initiation and promotion phases of chemical carcinogenesis. Cancer Res 41: 4386-4390, 1981.
2. Reddy BS, Sugie S, Maryyama S, El-Bayoumy K and Marra P: Chemoprevention of colon carcinogenesis by dietary organoselenium, benzylselenocyanate, in Fischer 344 rats. Cancer Res 47: 5901-5904, 1987.
3. Rao CV, Wang CQ, Simi B, Rodriguez JG, Cooma I, El-Bayoumy K and Reddy BS: Chemoprevention of colon cancer by a glutathione conjugate of 1,4-phenylenebis(methylene) selenocyanate, a novel organoselenium compound with low toxicity. Cancer Res 61: 3647-3652, 2001.
4. Rudolph RE, Vaughan TL, Kristal AR, Blount PL, Levine DS, Galipeau PC, Prevo LJ, Sanchez CA, Rabinovitch PS, and Reid BJ: Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagous. J Natl Cancer Inst 95: 750-757, 2003.
5. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL and Taylor JR: Effects of selenium supplementation for cancer chemoprevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276: 1957-1963, 1996.
6. Klein EA: Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: The selenium and vitamin E cancer prevention trial. Recent Results Cancer Res 163: 212-225, 2003.
7. Ip C and Lisk DJ: Bioactivity of selenium from Brazil nut, for cancer prevention and selenoenzyme maintenance. Nutr Cancer 21: 203-212, 1994.
8. Dong Y, Zhang H, Hawthorn L, Ganther HE and Ip C: Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 63: 52-59, 2003.
9. Seo YR, Kelley MR and Smith ML: Selehomethionine regulation of p53 by a Ref1-dependent redox mechanism. Proc Natl Acad Sci USA 99: 14548-14553, 2002.
10. Seo YR, Sweeney CJ and Smith ML: Selenomethionine induction of DNA repair response in human fibroblasts: Oncogene 21: 3663-3669, 2002.
11. Kuperwasser C, Hurlbut GD, Kittrell FS, Dickinson ES, Laucirica R, Medina D, Naber SP and Jerry DJ: Development of spontaneous mammary tumors in balb/c p53 heterozygous mice. Am J Pathol 157: 2151-2159, 2000.
12. Sinha R, Unni E, Ganther HE and Medina D: Methylseleninic acid, a potent growth inhibitor of synchronized mouse mammary epithelial tumor cells in vitro. Biochem Pharmacol 61: 311-317, 2001.
13. Wang Z, Jiang C and Lu J: Induction of caspase-mediated apoptosis and cell cycle G1 arrest by selenium metabolite methylselenol. Mol Carcing 34: 113-120, 2002.
14. Ip C, Thompson HJ, Zhu Z and Ganther HE: In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 60: 2882-2886, 2000.
15. Adimoolam S and Ford JM: P53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proc Natl Acad Sci USA 99: 12985-12990, 2002.
16. Hollander MC, Kovalsky O, Salvador JM, Kim KE, Patterson AD, Haines DC and Fornace AJ Jr: Dimethylbenzanthracene carcinogenesis in Gadd45a-null mice is associated with decreased DNA repair and increased mutation frequency. Cancer Res 61: 2487-2491, 2001.
17. Smith ML, Ford JM, Hollander MC, Bortnick RA, Amundson SA, Seo YR, Deng C, Hanawalt PC and Fornace AJ Jr: P53-mediated DNA repair responses to UV-radiation: Studies of mouse cells lacking p53, p21 and/or gadd45 genes. Mol Cell Biol 20: 3705-3714, 2000.
18. Norgauer J, Idzko M, Panther E, Hellstern O and Herouy Y: Xeroderma pigmentosum. Eur J Dermatol 13: 4-9, 2003.
19. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B and Fornace AJ Jr: A mammalian cell cycle checkpoint pathway utilizing p53 and Gadd45 is defective in ataxia telangiectasia. Cell 71: 587-597, 1992.
20. Smith ML, Chen IT, Zhan Q, O'Connor PM and Fornace AJ Jr: Involvement of the p53 tumor suppressor gene in repair of UV-type DNA damage. Oncogene 10: 1053-1059, 1995.
21. Jayaraman L, Murthy KG, Zhu C, Curran T, Xanthoudakis S and Prives C: Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev 11: 558-570, 1997.
22. Gaiddon C, Moorthy NC and Prives C: Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo. EMBO J 18: 5609-5621, 1999.
23. Hainaut P and Mann K: Zinc binding and redox control of p53 structure and function. Antiox Redox Signal 3: 611-623, 2001.
24. Smith ML and Fornace AJ Jr: P53-mediated protective responses to UV-irradiation. Proc Natl Acad Sci USA 94: 12255-12257, 1997.
25. Pluquet O and Hainaut P: Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett 174: 1-15, 2001.
26. Lanfear J, Fleming J, Wu L, Webster G and Harrison PR: The selenium metabolite selenodiglutathione induces p53: relevance to the chemopreventive effects of selenium? Carcinogenesis 15: 1387-1392, 1994.
27. Hwang BJ, Ford JM, Hanawalt PC and Chu G: Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc Natl Acad Sci USA 96: 424-8, 1999.
28. Ford JM and Hanawalt PC: Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. J Biol Chem 272: 28073-28080, 1997.
29. Cistulli CA and Kaufmann WK: P53-dependent signaling sustains DNA replication and enhances clonogenic survival in 254 nm UV-irradiated human fibroblasts. Cancer Res 58: 1993-2002, 1998.
30. Adimoolam S and Ford JM: P53 and regulation of DNA damage recognition during nucleotide excision repair. DNA Repair (Amst) 2: 947-954, 2003
31. Sugasawa K, Shimizu Y, Iwai S and Hanaoka F: A molecular mechanism for DNA damage recognition by the xeroderma pigmentosum group C protein complex. DNA Repair (Amst) 1: 95-107, 2002.
32. Friedberg EC, Bond JP, Burns DK, Cheo DL, Greenblatt MS, Meira LB, Nahari D and Reis AM: Defective nucleotide excision repair in xpc mutant mice and its association with cancer predisposition. Mutat Res 459: 99-108, 2000.
33. Grossman L: Nucleotide excision repair: Dick Setlow: how he influenced my scientific life. Environ Mol Mutagen 38: 144-52, 2001.
34. Dong Y, Ip C and Ganther H: Evidence of a field effect associated with mammary cancer chemoprevention by methylseleninic acid. Anticancer Res 22: 27-32, 2002.
35. Bresson A and Fuchs RPP: Lesion bypass in yeast cells: Pol eta participates in a multi-DNA polymerase process. EMBO J 21: 3881-7, 2002.
36. Ames B and Gold LS: The causes and prevention of cancer: gaining perspective. Environ Health Perspect 105 suppl. 14: 865-873, 1997.
37. Redman C, Scott JA, Baines AT, Basye JL, Clark LC, Calley C, Payne CM and Nelson MA: Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett 125: 103-110, 1998.
38. Evans AR, Limp-Foster M and Kelley MR: Going APE over ref-1. Mutat Res 461: 83-108, 2000.
39. Seo YR, Fishel ML, Amundson SA, Kelley MR and Smith ML: Implication of p53 in base excision DNA repair: in vivo evidence. Oncogene 21: 731-737, 2002.
40. Wei SJ, Botero A, Hirota K, Bradbury CM, Markovina S, Laszlo A, Spitz DR, Goswami PC, Yodoi J and Gius D: Thioredoxin nuclear translocation and interaction with redox factor-1 (Ref-1) activates the activator protein-1 transcription factor in response to ionizing radiation. Cancer Res 60: 6688-6695, 2000.
41. Allan CB, Lacourciere GM and Stadtman TC: Responsiveness of selenoproteins to dietary selenium. Ann Rev Nutr 19: 1-16, 1999.
42. Mosharov E, Cranford MR and Banerjee R: The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes. Biochemistry 39: 13005-13011, 2000.
43. Ueno M, Masutani H, Arai RJ, Yamauchi A, Hirota K, Sakai T, Inamoto T, Yamaoka Y, Yodoi J and Nikaido T: Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 274: 35809-35815, 1999.
44. Zhan Q, Fan S, Smith ML, Bae I, Yu K, Alamo I, O'Connor PM and Fornace AJ Jr: Abrogation of p53 function affects gadd gene responses to DNA base-damaging agents and starvation. DNA Cell Biol 15: 805-815, 1996.